Adam L Green, Patrick Flannery, Todd C Hankinson, Brent O'Neill, Vladimir Amani, John DeSisto, Aaron Knox, Hannah Chatwin, Rakeb Lemma, Lindsey M Hoffman, Jean Mulcahy Levy, Jennifer Raybin, Molly Hemenway, Ahmed Gilani, Carl Koschmann, Nathan Dahl, Michael Handler, Angela Pierce, Sujatha Venkataraman, Nicholas Foreman, Rajeev Vibhakar, Michael F Wempe, Kathleen Dorris
BACKGROUND: Hundreds of systemic chemotherapy trials in diffuse intrinsic pontine glioma (DIPG) have not improved survival, potentially due to lack of intratumoral penetration, which has not previously been assessed in humans. METHODS: We used gemcitabine as a model agent to assess DIPG intratumoral pharmacokinetics (PK) using mass spectrometry. RESULTS: In a phase 0 clinical trial of i.v. gemcitabine prior to biopsy in children newly diagnosed with DIPG by MRI, mean concentration in 4 biopsy cores in patient 1 (H3K27M diffuse midline glioma) was 7...
January 2020: Neuro-oncology advances